William Blair Raises Earnings Estimates for Krystal Biotech

Krystal Biotech, Inc. (NASDAQ:KRYS) – Stock analysts at William Blair upped their Q1 2025 earnings per share estimates for shares of Krystal Biotech in a research note issued on Wednesday, February 19th. William Blair analyst S. Corwin now forecasts that the company will post earnings of $1.47 per share for the quarter, up from their previous estimate of $1.25. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share. William Blair also issued estimates for Krystal Biotech’s Q2 2025 earnings at $1.64 EPS, Q3 2025 earnings at $1.82 EPS, Q4 2025 earnings at $2.11 EPS, FY2025 earnings at $7.04 EPS and FY2026 earnings at $9.97 EPS.

Other equities analysts have also recently issued research reports about the company. Chardan Capital lifted their target price on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research note on Wednesday, February 19th. Citigroup lifted their target price on Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Krystal Biotech in a research note on Thursday. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $210.00.

Krystal Biotech Price Performance

NASDAQ:KRYS opened at $187.86 on Monday. Krystal Biotech has a fifty-two week low of $107.50 and a fifty-two week high of $219.34. The stock’s 50-day moving average is $157.85 and its two-hundred day moving average is $175.26. The stock has a market cap of $5.41 billion, a PE ratio of 62.83 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same quarter in the previous year, the company earned $0.30 EPS. The business’s revenue for the quarter was up 116.4% compared to the same quarter last year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Wilmington Savings Fund Society FSB acquired a new position in shares of Krystal Biotech in the third quarter valued at $40,000. GF Fund Management CO. LTD. bought a new stake in shares of Krystal Biotech during the fourth quarter worth $95,000. Huntington National Bank boosted its holdings in Krystal Biotech by 97.6% in the third quarter. Huntington National Bank now owns 573 shares of the company’s stock valued at $104,000 after acquiring an additional 283 shares during the last quarter. Blue Trust Inc. boosted its holdings in Krystal Biotech by 242.4% in the third quarter. Blue Trust Inc. now owns 582 shares of the company’s stock valued at $107,000 after acquiring an additional 412 shares during the last quarter. Finally, Covestor Ltd boosted its holdings in Krystal Biotech by 972.7% in the fourth quarter. Covestor Ltd now owns 708 shares of the company’s stock valued at $111,000 after acquiring an additional 642 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the transaction, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 14.10% of the stock is currently owned by company insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).